AR078351A1 - Inhibidores de la hsl para el tratamiento de la diabetes - Google Patents
Inhibidores de la hsl para el tratamiento de la diabetesInfo
- Publication number
- AR078351A1 AR078351A1 ARP100103302A ARP100103302A AR078351A1 AR 078351 A1 AR078351 A1 AR 078351A1 AR P100103302 A ARP100103302 A AR P100103302A AR P100103302 A ARP100103302 A AR P100103302A AR 078351 A1 AR078351 A1 AR 078351A1
- Authority
- AR
- Argentina
- Prior art keywords
- piperidine
- phenyl
- methoxy
- benzenesulfonyl
- carboxylic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Proceso de obtencion, composiciones farmacéuticas y usos. Reivindicacion 1: Compuesto de la formula (1) en la que R1 es dimetilpropilo, dimetilbutilo, ciclopropilalquilo, pirazolilo, metil-trifluorometil-1H-pirazolilo, morfolinilo, fenilo, 2-clorofenilo, 4-metilfenilo o 4-metoxifenilo; R2 es hidrogeno, alquilo, hidroxialquilo o alcoxialquilo; R3 es hidrogeno, alquilo, hidroxialquilo o alcoxialquilo; R4 es hidrogeno, halogeno, alquilo, hidroxialquilo o alcoxialquilo; R5 es hidrogeno o alquilo; R6 es 2,3-dihidro-benzofuranilo, alquilpiridin-3-ilo, haloalcoxipiridin-3-ilo, piridazinilo, alcoxipiridazinilo, alquil-trifluorometil-1H-pirazolilo, fenilo o fenilo sustituido, dicho fenilo sustituido es un fenilo sustituido en la posicion 4 por un sustituyente elegido entre cloro, isopropilo, hidroxialquilo, isopropoxi, cicloalquilalcoxi, haloalcoxi, haloalcoxialquilo, alcoxicarbonilalcoxi, carboxialcoxi, hidroxialcoxi, alcoxihaloalcoxi e hidroxihaloalcoxi y, dicho fenilo sustituido en la posicion 4 está además opcionalmente sustituido por un sustituyente elegido con independencia entre fluor, trifluormetoxi, alcoxicarbonilalcoxi e hidroxialcoxicarbonilo, pero en el caso, en el que R6 sea fenilo o fenilo sustituido en la posicion 4 por cloro, entonces A2 es G; A1 es carbonilo o -S(O)2-; A2 es un enlace sencillo, -CH2CH2- o G; G es un resto de formula (2); n es el numero cero, 1, 2, 3, 4 o 5; y sus sales farmacéuticamente aceptables; con la condicion de que se excluyan la (4-trifluorometoxi-fenil)-amida del ácido 1-(tolueno-4-sulfonil)-piperidina-4-carboxílico; [2-(4-difluorometoxi-fenil)-etil]-amida del ácido 1-(tolueno-4-sulfonil)-piperidina-4-carboxílico; (4-iso-propil-fenil)-amida del ácido 1-bencenosulfonil-piperidina-4-carboxílico; (4-isopropil-fenil)-amida del ácido 1-(tolueno-4-sulfonil)-piperidina-4-carboxílico (4-trifluorometoxi-fenil)-amida del ácido 1-(4-metoxi-bencenosulfonil)-piperidina-4-carboxílico; (4-trifluorometoxi-fenil]-amida del ácido 1-bencenosulfonil-piperidina-4-carboxílico; (4-difluoro-metoxi-fenil)-amida del ácido 1-(4-metoxi-bencenosulfonil)-piperidina-4-carboxílico; (4-isopropil-fenil)-amida del ácido 1-(4-metoxi-bencenosulfonil)-piperidina-4-carboxílico; (4-cloro-2-fluor-fenil)-amida del ácido 1-(4-metoxi-benceno-sulfonil)-piperidina-4-carboxílico; (4-isopropil-fenil)-amida del ácido 1-benzoil-piperidina-4-carboxílico; (4-isopropil-fenil)-amida del ácido 1-(2-cloro-benzoil)-piperidina-4-carboxílico; (1-fenil-ciclopropilmetil)-amida del ácido 1-bencenosulfonil-piperidina-4-carboxílico y (1-fenil-ciclo-pentilmetil)-amida del ácido 1-(tolueno-4-sulfonil)-piperidina-4-carboxílico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09170071 | 2009-09-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR078351A1 true AR078351A1 (es) | 2011-11-02 |
Family
ID=42983383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100103302A AR078351A1 (es) | 2009-09-11 | 2010-09-09 | Inhibidores de la hsl para el tratamiento de la diabetes |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8258158B2 (es) |
| EP (1) | EP2475644B1 (es) |
| JP (1) | JP5642793B2 (es) |
| KR (1) | KR101369551B1 (es) |
| CN (1) | CN102498099B (es) |
| AR (1) | AR078351A1 (es) |
| AU (1) | AU2010294326A1 (es) |
| BR (1) | BR112012005140A2 (es) |
| CA (1) | CA2771452A1 (es) |
| ES (1) | ES2445166T3 (es) |
| HK (1) | HK1169993A1 (es) |
| IL (1) | IL217966A0 (es) |
| IN (1) | IN2012DN01232A (es) |
| MX (1) | MX2012002597A (es) |
| SG (1) | SG179031A1 (es) |
| TW (1) | TW201114744A (es) |
| WO (1) | WO2011029808A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5951650B2 (ja) | 2011-03-18 | 2016-07-13 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | Ｎ−（３−カルバモイルフェニル）−１ｈ−ピラゾール−５−カルボキサミド誘導体及び害虫を防除するためのそれらの使用 |
| WO2014037327A1 (en) * | 2012-09-10 | 2014-03-13 | Boehringer Ingelheim International Gmbh | N-cyclopropyl-n-piperidinyl-amides, pharmaceutical compositions containing them, and uses thereof |
| US10793522B2 (en) * | 2016-12-09 | 2020-10-06 | Boehringer Ingelheim International Gmbh | Sulfonamides as inhibitors of the uptake of extracellular citrate |
| GB2560713A (en) * | 2017-03-20 | 2018-09-26 | Eternygen Gmbh | Inhibitor of citrate transporter |
| CN110003177B (zh) * | 2019-05-28 | 2021-11-19 | 沈阳药科大学 | 含有脲基的苯并咪唑类化合物及应用 |
| CN110003176B (zh) * | 2019-05-28 | 2021-12-21 | 沈阳药科大学 | 含有酰胺的苯并咪唑类化合物及其应用 |
| GB201918410D0 (en) * | 2019-12-13 | 2020-01-29 | Z Factor Ltd | Compounds and their use for the treatment of alpha1-antitrypsin deficiency |
| WO2022130352A1 (en) * | 2020-12-19 | 2022-06-23 | Cadila Healthcare Limited | Novel compounds suitable for the treatment of dyslipidemia |
| GB202108523D0 (en) | 2021-06-15 | 2021-07-28 | Z Factor Ltd | Compositions and their use for the treatment of alpha1-antitrypsin deficiency |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3779339B2 (ja) | 1994-03-04 | 2006-05-24 | 三井化学株式会社 | 含フッ素カルボン酸エステル化合物、液晶材料、液晶組成物および液晶素子 |
| EP1087937A1 (en) * | 1998-06-17 | 2001-04-04 | Du Pont Pharmaceuticals Company | Cyclic hydroxamic acids as metalloproteinase inhibitors |
| US7071213B2 (en) | 2001-11-14 | 2006-07-04 | Schering Corporation | Cannabinoid receptor ligands |
| MX2007010532A (es) * | 2005-03-03 | 2007-10-12 | Hoffmann La Roche | Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii. |
| JP2009526761A (ja) * | 2006-01-30 | 2009-07-23 | アレイ バイオファーマ、インコーポレイテッド | ヘテロ二環式チオフェン化合物および使用の方法 |
| WO2007144394A2 (en) * | 2006-06-16 | 2007-12-21 | High Point Pharmaceuticals, Llc. | Pharmaceutical use of substituted piperidine carboxamides |
| EP1958631A1 (en) | 2007-02-14 | 2008-08-20 | AEterna Zentaris GmbH | Novel triazole derivatives as ligands of G-protein coupled receptors |
| US8324250B2 (en) | 2009-03-19 | 2012-12-04 | Hoffmann-La Roche Inc. | Piperidine derivatives as NK3 receptor antagonists |
| US8329904B2 (en) * | 2009-05-12 | 2012-12-11 | Hoffmann-La Roche Inc. | Azacyclic derivatives |
| US8399676B2 (en) * | 2009-07-30 | 2013-03-19 | Hoffman-La Roche Inc. | Piperidine derivatives |
-
2010
- 2010-09-03 US US12/875,446 patent/US8258158B2/en not_active Expired - Fee Related
- 2010-09-07 JP JP2012528339A patent/JP5642793B2/ja not_active Expired - Fee Related
- 2010-09-07 WO PCT/EP2010/063078 patent/WO2011029808A1/en active Application Filing
- 2010-09-07 CA CA2771452A patent/CA2771452A1/en not_active Abandoned
- 2010-09-07 ES ES10751931.6T patent/ES2445166T3/es active Active
- 2010-09-07 CN CN201080039803.8A patent/CN102498099B/zh not_active Expired - Fee Related
- 2010-09-07 BR BR112012005140A patent/BR112012005140A2/pt not_active Application Discontinuation
- 2010-09-07 MX MX2012002597A patent/MX2012002597A/es active IP Right Grant
- 2010-09-07 AU AU2010294326A patent/AU2010294326A1/en not_active Abandoned
- 2010-09-07 KR KR1020127009254A patent/KR101369551B1/ko not_active IP Right Cessation
- 2010-09-07 EP EP10751931.6A patent/EP2475644B1/en not_active Not-in-force
- 2010-09-07 SG SG2012016085A patent/SG179031A1/en unknown
- 2010-09-07 IN IN1232DEN2012 patent/IN2012DN01232A/en unknown
- 2010-09-08 TW TW099130350A patent/TW201114744A/zh unknown
- 2010-09-09 AR ARP100103302A patent/AR078351A1/es unknown
-
2012
- 2012-02-06 IL IL217966A patent/IL217966A0/en unknown
- 2012-10-30 HK HK12110838.1A patent/HK1169993A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| IN2012DN01232A (es) | 2015-05-15 |
| US20110065707A1 (en) | 2011-03-17 |
| HK1169993A1 (en) | 2013-02-15 |
| MX2012002597A (es) | 2012-04-02 |
| IL217966A0 (en) | 2012-03-29 |
| KR101369551B1 (ko) | 2014-03-04 |
| ES2445166T3 (es) | 2014-02-28 |
| JP2013504533A (ja) | 2013-02-07 |
| EP2475644A1 (en) | 2012-07-18 |
| CN102498099A (zh) | 2012-06-13 |
| TW201114744A (en) | 2011-05-01 |
| KR20120059617A (ko) | 2012-06-08 |
| CA2771452A1 (en) | 2011-03-17 |
| US8258158B2 (en) | 2012-09-04 |
| WO2011029808A1 (en) | 2011-03-17 |
| SG179031A1 (en) | 2012-04-27 |
| CN102498099B (zh) | 2014-10-29 |
| EP2475644B1 (en) | 2014-01-08 |
| AU2010294326A1 (en) | 2012-03-08 |
| JP5642793B2 (ja) | 2014-12-17 |
| BR112012005140A2 (pt) | 2016-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR078351A1 (es) | Inhibidores de la hsl para el tratamiento de la diabetes | |
| NO20082090L (no) | Pyridopyrimidinoninhibitorer av P13K alfa | |
| TN2009000199A1 (en) | Heteromonocyclic compound and use thereof | |
| BR112012007069A2 (pt) | derivado de fenol | |
| NO20092286L (no) | Nitrogenhaldige heterosykliske forbindelser og anvendelse derav | |
| PE20081362A1 (es) | DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K | |
| AR064459A1 (es) | Derivados de sulfonamida | |
| AR097024A1 (es) | Derivados sustituidos de quinazolin-4-ona | |
| AR063680A1 (es) | Derivados de pirazolo[1, 5-a]pirimidina, metodos e intermediario para su preparacion, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la modulacion de mglur5. | |
| PE20080890A1 (es) | DERIVADOS DE IMIDAZOLONA E IMIDAZOLIDINONA COMO INHIBIDORES DE LA 11b-HSD1 PARA LA DIABETES | |
| AR048289A1 (es) | Eteres de anillos imidazo sulfona sustituidos. | |
| AR047812A1 (es) | Compuestos de tetrazol y su uso como antagonistas del receptor de glutamato metabotropico | |
| AR060651A1 (es) | Derivados de 1,2,4-triazol como moduladores de mglur5 i, intermediarios para su sintesis, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del dolor y de trastornos gastrointestinales | |
| UY29047A1 (es) | Derivados de sulfonamidas, su preparación y su aplicación en terapéutica | |
| AR063101A1 (es) | Derivados de pirazina-2-carboxiamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento o profilaxis de enfermedades asociadas con la modulacion de receptores del cb2. | |
| PE20121471A1 (es) | Derivados de sulfonamida heterociclicos utiles como inhibidores de mek | |
| PE20090820A1 (es) | Derivados de piperidina/piperazina | |
| AR066107A1 (es) | Derivados de triazolopiridin - carboxamidas y triazolopirimidin-carboxamidas, su preparacion y su aplicacion en terapeutica como inhibidores de la enzimamonoacil glicerol lipasa y composiciones qu los contienen. | |
| CO6220935A2 (es) | Derivados de 1,2,4-triazol como moduladores de mglur5 | |
| AR052450A1 (es) | Derivados de n-(heteroaril)-1h- indol-2-carboxamidas , supreparacion y su aplicacion en terapeutica | |
| NO20076680L (no) | Utvalgte CGRP-antagonister, metoder for fremstilling av disse og deres anvendelse som medikamenter | |
| AR070485A1 (es) | Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica | |
| AR055744A1 (es) | Derivados de acido pirimidincarboxilico, su uso para preparar medicamentos y preparacion de dicjhos compuestos | |
| AR060810A1 (es) | Moduladores de receptores metabotropicos de glutamato mglur5, composiciones farmaceuticas que los contienen y usos en procesos patofisiologicos y trastornos que afectan el scn | |
| AR070431A1 (es) | Derivados de piridona y piridazinona y composiciones farmaceuticas que comprenden estos compuestos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |